| Exercise to Boost Response to Checkpoint Blockade Immunotherapy (NCT05358938) | H. Lee Moffitt Cancer Center and Research Institute | 2022-06-21 |
| MelaMEd Online Training for General Practitioners to Improve Melanoma Detection and Management (NCT07757386) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2022-06-01 |
| Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors (NCT04253080) | Assistance Publique - Hôpitaux de Paris | 2022-04-12 |
| Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer (NCT05267626) | Aulos Bioscience, Inc. | 2022-04-04 |
| The MELAcare Study: A New Method for Surveillance of Melanoma Patients (NCT05253872) | Herlev and Gentofte Hospital | 2022-03-09 |
| RTX-224 Monotherapy in Patients With Solid Tumors (NCT05219578) | Rubius Therapeutics | 2022-01-12 |
| Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS) (NCT07376317) | Instituto do Cancer do Estado de São Paulo | 2021-12-10 |
| Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6 (NCT04830124) | Mural Oncology, Inc | 2021-09-27 |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (NCT05059444) | Guardant Health, Inc. | 2021-09-07 |
| A Beta-only IL-2 ImmunoTherapY Study (NCT05086692) | Medicenna Therapeutics, Inc. | 2021-08-27 |
| Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours (NCT04855435) | MonTa Biosciences ApS | 2021-04-12 |
| TH1902 in Patients With Advanced Solid Tumors (NCT04706962) | Theratechnologies | 2021-03-04 |
| Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma (NCT03929029) | Dana-Farber Cancer Institute | 2020-11-11 |
| A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas (NCT04551352) | Hoffmann-La Roche | 2020-10-28 |
| Neoadjuvant Atezolizumab in Cutaneous Melanoma (NCT04020809) | The Methodist Hospital Research Institute | 2020-09-25 |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer (NCT04254107) | Seagen Inc. | 2020-05-29 |
| Neoadjuvant Combination Immunotherapy for Stage III Melanoma (NCT03842943) | University of Louisville | 2019-07-03 |
| Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (NCT03947385) | IDEAYA Biosciences | 2019-06-28 |
| A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery (NCT03843593) | Memorial Sloan Kettering Cancer Center | 2019-02-14 |
| MGD019 DART® Protein in Unresectable/Metastatic Cancer (NCT03761017) | MacroGenics | 2018-12-12 |
| Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma (NCT03620019) | UNC Lineberger Comprehensive Cancer Center | 2018-09-10 |
| Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine (NCT03633110) | Genocea Biosciences, Inc. | 2018-08-29 |
| A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors (NCT03611868) | Ascentage Pharma Group Inc. | 2018-08-29 |
| MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma (NCT03699995) | OHSU Knight Cancer Institute | 2018-05-18 |
| Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) (NCT03767348) | Replimune, Inc. | 2017-09-20 |
| Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma (NCT02968680) | University of Southern California | 2017-04-26 |
| A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (NCT02791334) | Eli Lilly and Company | 2016-06-29 |
| A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes (NeoEpitope) (NCT02831634) | Institut Curie | 2016-06-09 |
| Advanced Non-invasive Diagnostics for Early Cutaneous Tumor Diagnosis, Clinical-therapeutic and Economic Management (NCT04789421) | Azienda Ospedaliero-Universitaria di Modena | 2016-03-01 |
| Neoadjuvant and Adjuvant Checkpoint Blockade (NCT02519322) | M.D. Anderson Cancer Center | 2016-02-02 |
| Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma (NCT04778449) | M.D. Anderson Cancer Center | 2015-08-26 |
| PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma (NCT02288897) | Provectus Biopharmaceuticals, Inc. | 2015-04-01 |
| Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome (NCT04792463) | Mohamed Abdel-Rahman | 2015-03-03 |
| 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results (NCT02355574) | Castle Biosciences Incorporated | 2014-06-01 |
| A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma (NCT02129075) | National Cancer Institute (NCI) | 2014-04-09 |
| Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes (NCT02355587) | Castle Biosciences Incorporated | 2014-03-01 |
| Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma (NCT04274816) | A.J.M. van den Eertwegh | 2012-07-10 |
| Minimal SN Tumor Burden (NCT01942603) | European Organisation for Research and Treatment of Cancer - EORTC | 2009-07-01 |
| Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients (NCT01729663) | Laboratorio Pablo Cassara S.R.L. | 2009-04-01 |
| miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi (NCT01444560) | Ruhr University of Bochum | 2008-12-01 |
| Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma (NCT00679289) | Ludwig Institute for Cancer Research | 2008-03-28 |
| Location of Lower Limb Cutaneous Melanomas as a Prognostic Factor. (NCT04625491) | Hospital Universitario Virgen de la Arrixaca | 2000-01-01 |
| Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver (NCT01728051) | Delcath Systems Inc. | |